tiprankstipranks
Trending News
More News >
Herbalife Ltd (HLF)
NYSE:HLF

Herbalife (HLF) AI Stock Analysis

Compare
488 Followers

Top Page

HL

Herbalife

(NYSE:HLF)

62Neutral
Herbalife's stock shows a mixed outlook. Strong operational efficiency is offset by financial risks, notably high leverage and declining sales. The stock's low P/E ratio suggests undervaluation, which could attract investors despite technical indicators showing little momentum. Strategic initiatives and EBITDA improvements are positive, but regional sales declines and market challenges are concerns.
Positive Factors
Acquisitions
HLF announced acquisitions of Pro2col Health, LinkBiosciences, and Pruvit Venture, expected to improve customer engagement and distributor productivity.
Leadership
New CEO Stephan Gratziani has a long-term vision and connects with top distributors, contributing positively to the company's future.
New Distributor Growth
The growth of new worldwide distributors accelerated, marking the third consecutive quarterly increase.
Negative Factors
App Usage
In Mexico, the trend of average active users of the Herbalife Shop app has softened sequentially and is now trending negative year over year.
Regional Performance
New distributor growth for HLF was +16% in 1Q25, but with the trend in N. America inflecting negative (-1%) and China continued to decline (-23%).
Web Traffic
Globally, the trends across web & app traffic have been consistently weak with a notable worsening in average unique visitors to myherbalife.com.

Herbalife (HLF) vs. S&P 500 (SPY)

Herbalife Business Overview & Revenue Model

Company DescriptionHerbalife Nutrition Ltd. offers nutrition solutions in North America, Mexico, South and Central America, Europe, the Middle East, Africa, China, and rest of Asia Pacific. The company provides products in the areas of weight management; targeted nutrition; energy, sports, and fitness; and outer nutrition. It offers weight management products, including meal replacement products, protein shakes, drink mixes, weight loss enhancers, and healthy snacks; targeted nutrition products, which comprise functional beverages, and dietary and nutritional supplements that contain herbs, vitamins, minerals, and other natural ingredients; outer nutrition products, such as facial skin, body, and hair care products; and energy, sports, and fitness products, including N-R-G tea and energy drink products. The company also provides literature, promotional, and other materials that comprise start-up kits, sales tools, and educational materials. It offers its products through independent service providers and sales representatives, as well as through company-operated retail platforms. The company was formerly known as Herbalife Ltd. and changed its name to Herbalife Nutrition Ltd. in April 2018. Herbalife Nutrition Ltd. was founded in 1980 and is headquartered in Los Angeles, California.
How the Company Makes MoneyHerbalife makes money primarily through a multi-level marketing (MLM) model, where independent distributors sell products directly to consumers. Distributors earn revenue through both retail sales and recruiting new distributors, who in turn sell products and expand the network. The company generates income from the sales of its diverse product line, including weight management, targeted nutrition, energy and fitness, and outer nutrition products. Herbalife also benefits from economies of scale and a global presence, which allows the company to leverage its extensive supply chain and distribution network. Key revenue streams include product sales to distributors and, indirectly, the recruitment and training of new distributors, which expand its customer base and market penetration.

Herbalife Financial Statement Overview

Summary
Herbalife's financial performance shows mixed results. While the gross profit margin remains robust, declining revenue and net profit margins indicate challenges. The balance sheet reveals significant leverage concerns with negative equity, and while cash flow generation is stable, it is offset by high financing outflows.
Income Statement
70
Positive
Herbalife's income statement shows a declining trend in total revenue over the past few years, with a recent TTM total revenue of $4.95 billion, down from $5.20 billion in 2022. The gross profit margin remains strong at approximately 77.39% for the TTM period, indicating efficient cost management. However, the net profit margin has decreased to 5.66% from higher levels in previous years, highlighting challenges in maintaining profitability. The EBIT margin for TTM stands at 9.08%, and EBITDA margin at 10.64%, both reflecting a stable yet pressured operating environment.
Balance Sheet
45
Neutral
The balance sheet reveals significant financial leverage, with a negative stockholders' equity of -$736 million as of TTM, indicating high debt levels relative to assets. The debt-to-equity ratio is not calculable due to negative equity, raising concerns about financial stability. The equity ratio is also negative, further emphasizing the risk associated with high indebtedness. Despite these challenges, total assets remain substantial at $2.68 billion.
Cash Flow
65
Positive
Herbalife's cash flow statement shows a modest free cash flow growth, with TTM free cash flow of $164.4 million, slightly higher than the previous year's $163.4 million. The operating cash flow to net income ratio is 0.97, indicating efficient cash conversion from net income. However, the high levels of financing cash outflows raise concerns about reliance on debt to fund operations.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
4.95B4.99B5.06B5.20B5.80B5.54B
Gross Profit
3.83B3.89B3.87B4.03B4.56B4.39B
EBIT
449.60M385.90M356.40M545.20M734.10M640.60M
EBITDA
560.40M509.10M482.20M672.70M854.60M740.90M
Net Income Common Stockholders
280.40M254.30M142.20M321.30M447.20M372.60M
Balance SheetCash, Cash Equivalents and Short-Term Investments
329.40M415.30M575.20M508.00M601.50M1.05B
Total Assets
2.68B2.73B2.81B2.73B2.82B3.08B
Total Debt
2.40B2.47B2.77B2.88B2.96B2.64B
Net Debt
2.07B2.05B2.19B2.38B2.36B1.59B
Total Liabilities
3.42B3.53B3.87B4.00B4.21B3.93B
Stockholders Equity
-736.00M-801.10M-1.06B-1.27B-1.39B-856.10M
Cash FlowFree Cash Flow
164.40M163.40M222.50M196.10M308.90M516.60M
Operating Cash Flow
271.80M285.40M357.50M352.50M460.30M628.60M
Investing Cash Flow
-70.60M-84.60M-134.80M-156.20M-156.40M-123.20M
Financing Cash Flow
-249.30M-335.30M-148.30M-264.70M-728.60M-320.90M

Herbalife Technical Analysis

Technical Analysis Sentiment
Negative
Last Price6.93
Price Trends
50DMA
7.49
Negative
100DMA
7.07
Negative
200DMA
7.42
Negative
Market Momentum
MACD
-0.09
Negative
RSI
48.18
Neutral
STOCH
56.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HLF, the sentiment is Negative. The current price of 6.93 is above the 20-day moving average (MA) of 6.92, below the 50-day MA of 7.49, and below the 200-day MA of 7.42, indicating a neutral trend. The MACD of -0.09 indicates Negative momentum. The RSI at 48.18 is Neutral, neither overbought nor oversold. The STOCH value of 56.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HLF.

Herbalife Risk Analysis

Herbalife disclosed 33 risk factors in its most recent earnings report. Herbalife reported the most risks in the “Legal & Regulatory” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Herbalife Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
$985.55M15.3621.57%25.92%
73
Outperform
$560.00M16.476.78%-2.69%-43.24%
68
Neutral
$1.27B-7.25%5.94%-115.82%
64
Neutral
$889.20M45.595.40%0.40%3.36%7.51%
HLHLF
62
Neutral
$705.80M2.52-31.74%-2.45%100.59%
59
Neutral
$904.51M-34.65%252.64%85.10%
52
Neutral
$5.19B3.04-44.64%2.82%16.45%-0.53%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HLF
Herbalife
6.93
-4.30
-38.29%
AORT
Artivion
29.71
6.25
26.64%
AVDL
Avadel Pharmaceuticals
9.35
-6.65
-41.56%
HSTM
HealthStream
29.13
1.82
6.66%
USNA
USANA Health
30.07
-19.70
-39.58%
CDNA
CareDx
17.70
2.57
16.99%

Herbalife Earnings Call Summary

Earnings Call Date:Apr 30, 2025
(Q1-2025)
|
% Change Since: -3.75%|
Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted strategic acquisitions and product innovation as key initiatives for future growth. However, challenges were evident in the form of declining net sales, significant FX impacts, and volume declines in key markets like North America and China. While there are positive signs in distributor growth and debt reduction, the mixed regional performance and sales decline create a balanced outlook.
Q1-2025 Updates
Positive Updates
Net Sales and Constant Currency Growth
Net sales of $1.2 billion were down 3.4% versus Q1 2024 but saw a constant currency growth of 1.4% year-over-year, marking the second consecutive quarter of year-over-year growth excluding FX headwinds.
Debt Reduction Milestone Achieved
Reduced total leverage ratio to three times as of March 31st, nine months ahead of the planned target.
New Distributor Growth
The number of new distributors joining Herbalife worldwide increased by 16% year-over-year, marking the fourth consecutive quarter of new distributor growth.
Pro2col Platform and Acquisitions
Announced planned asset acquisitions of Pro2col Health, Pruvit Ventures, and Link BioSciences, with a focus on personalized health solutions and expanding product offerings in the health and wellness sector.
Strong Adjusted EBITDA
First quarter adjusted EBITDA was $165 million, above the guidance range of $140 million to $150 million, with adjusted EBITDA margins of 13.5%, up 260 basis points versus Q1 of last year.
Negative Updates
Net Sales Decline
Net sales declined by 3.4% versus Q1 2024, with a significant negative impact from FX rates contributing to a 480 basis point headwind.
Volume Decline in Key Markets
North America experienced a 4% year-over-year decline in net sales, primarily driven by an 8% reduction in volumes. China also saw a 14% year-over-year decrease in net sales, driven by a similar decline in volumes.
Mixed Regional Performance
Latin America, EMEA, and Asia Pacific reported mixed regional performance, with FX negatively impacting reported net sales despite some local currency growth.
Company Guidance
During the first quarter of 2025, Herbalife Limited reported net sales of $1.2 billion, marking a 3.4% decrease compared to Q1 2024, but a 1.4% increase on a constant currency basis. The company achieved adjusted EBITDA of $165 million, surpassing their guidance range, with EBITDA margins improving by 260 basis points to 13.5%. Herbalife also successfully reduced its total leverage ratio to three times, achieving this target nine months ahead of schedule. The number of new distributors joining Herbalife increased by 16% year-over-year, marking the fourth consecutive quarter of such growth. Additionally, Herbalife completed asset acquisitions of Pro2col Health, Pruvit Ventures, and Link BioSciences to support future growth in health and wellness, with plans to launch a beta version of the Pro2col platform by the end of July and a commercial release in the U.S. in the fourth quarter. The company raised its full-year adjusted EBITDA guidance, now expecting a range of $625 million to $655 million, while also adjusting capital expenditures to $90 million to $120 million.

Herbalife Corporate Events

M&A TransactionsBusiness Operations and StrategyFinancial Disclosures
Herbalife Reports Q1 2025 Financial Results
Neutral
Apr 30, 2025

Herbalife reported its financial results for the first quarter of 2025, with net sales reaching $1.2 billion, down 3.4% from the previous year, but showing a 1.4% increase on a constant currency basis. The company exceeded its guidance for adjusted EBITDA and improved its gross profit margin. Recent strategic acquisitions, including Pro2col Health LLC and Pruvit Ventures, are expected to enhance Herbalife’s product offerings and market reach. The company also revised its full-year guidance, narrowing its net sales range and raising its adjusted EBITDA expectations.

Spark’s Take on HLF Stock

According to Spark, TipRanks’ AI Analyst, HLF is a Neutral.

Herbalife’s overall stock score is 47, reflecting significant financial challenges with declining revenues and high leverage. While there are positive developments in leadership and earnings guidance, technical indicators and regional sales declines suggest caution. The stock appears undervalued, offering potential upside if strategic initiatives succeed, but risks remain substantial.

To see Spark’s full report on HLF stock, click here.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.